echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: Acquired platelet GPVI receptor dysfunction suggests early sepsis!

    Blood: Acquired platelet GPVI receptor dysfunction suggests early sepsis!

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Center point:

    Center point:

    Patients with sepsis present with acquired platelet function defects and massive loss of GPVI receptor reactivity

    Patients with sepsis present with acquired platelet function defects and massive loss of GPVI receptor reactivity

    Platelet GPVI dysfunction is already obvious in the early stage of the disease and will recover after the patient recovers

    Platelet GPVI dysfunction is already obvious in the early stage of the disease and will recover after the patient recovers

    Glycoprotein VI (GPVI) is a platelet immune receptor tyrosine activated motif (ITAM) receptor for collagen , which plays an important role in vascular integrity in animal models of inflammation and sepsis


    Glycoprotein VI (GPVI) is a platelet immune receptor tyrosine activated motif (ITAM) receptor for collagen , which plays an important role in vascular integrity in animal models of inflammation and sepsis .


    In this flight study, 15 sepsis patients were continuously and comprehensively analyzed by flow cytometry, agglutination assay, and western blotting on the day they entered the intensive care unit (ICU), day 5 to day 7, and the day they were transferred out of the ICU


    Decreased platelet activity in patients with sepsis

    Decreased platelet activity in patients with sepsis

    The analysis results showed that the platelet function of all patients was significantly reduced


    The platelet function of all patients was significantly reduced .


    Co-culture with whole blood of patients with sepsis can induce GPVI deficiency in platelets from healthy donors

    Co-culture with whole blood of patients with sepsis can induce GPVI deficiency in platelets from healthy donors

    The platelets of patients with sepsis cannot transduce GPVI-mediated signals to trigger the tyrosine phosphorylation of Syk kinase or LAT


    Co-culture of platelets from healthy donors with whole blood of patients with sepsis can induce partial GPVI defects in platelets of healthy donors, but co-culture with plasma from patients with sepsis has no such effect

    In summary, since the weakening of GPVI signal occurs in the early stage of sepsis, this defect may be used as an indicator for the diagnosis of early sepsis , which needs to be further confirmed in prospective studies


    Since GPVI signal reduction occurs early onset of sepsis, the defect or as diagnostic indicators of early sepsis early onset signal reduction occurs due GPVI sepsis, or as the defect diagnostic indicator of early sepsis diagnosis

    Original source:

    Original source:

    Weiss Lukas J,Manukjan Georgi,Pflug Annerose et al.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.